Active Not Recruiting INTERVENTIONAL NCT05848258

An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Sponsor: Eli Lilly and Company

Conditions Rheumatoid Arthritis

Interventions LY3871801 Placebo

Updated 21 times since 2023 Last updated: Apr 20, 2026 Started: May 23, 2023 Primary completion: Dec 8, 2025 Completion: Apr 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Rheumatoid Arthritis, this trial is ongoing. The trial is conducted by Eli Lilly and Company and has accumulated 21 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

21 versions recorded

Apr 28, 2026 — Present [daily]

Active Not Recruiting

Status: Recruiting → Active Not Recruiting · Phase: PHASE2 → None
Jan 2026 — Apr 2026 [monthly]

Recruiting PHASE2
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE2
Oct 2025 — Dec 2025 [monthly]

Recruiting PHASE2
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE2

▶ Show 16 earlier versions

Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE2
Jun 2025 — Aug 2025 [monthly]

Recruiting PHASE2
May 2025 — Jun 2025 [monthly]

Recruiting PHASE2
Mar 2025 — May 2025 [monthly]

Recruiting PHASE2
Jan 2025 — Mar 2025 [monthly]

Recruiting PHASE2
Oct 2024 — Jan 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Mar 2024 — Jun 2024 [monthly]

Recruiting PHASE2
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE2
Nov 2023 — Feb 2024 [monthly]

Recruiting PHASE2
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE2
Aug 2023 — Oct 2023 [monthly]

Recruiting PHASE2
Jun 2023 — Aug 2023 [monthly]

Recruiting PHASE2

First recorded

May 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).

Contact Information

Sponsor contact:

Eli Lilly and Company
Rigel Pharmaceuticals

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahmedabad, India , Bellevue, United States , Bialystok, Poland , Brooklyn, United States , Budapest, Hungary , Budapest, Hungary , Buenos Aires, Argentina , Buenos Aires, Argentina , Buenos Aires, Argentina , Bytom, Poland and 44 more locations